{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T14:22:05Z","timestamp":1766067725965,"version":"3.37.3"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T00:00:00Z","timestamp":1684281600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009129","name":"Evidence Synthesis Programme","doi-asserted-by":"publisher","award":["NIHR133733"],"award-info":[{"award-number":["NIHR133733"]}],"id":[{"id":"10.13039\/501100009129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>As part of the Single Technology Appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited Apellis Pharmaceuticals\/Sobi to submit evidence for the clinical and cost effectiveness of pegcetacoplan versus eculizumab and pegcetacoplan versus ravulizumab for treating paroxysmal nocturnal haemoglobinuria (PNH) in adults whose anaemia is uncontrolled after treatment with a C5 inhibitor. The Liverpool Reviews and Implementation Group at the University of Liverpool was commissioned as the Evidence Review Group (ERG). The company pursued a low incremental cost-effectiveness ratio (ICER) Fast Track Appraisal (FTA). This was a form of STA processed in a shorter time frame and designed for technologies with company base-case ICER &lt; \u00a310,000 per quality-adjusted life-year (QALY) gained and most plausible ICER &lt; \u00a320,000 per QALY gained. This article summarises the ERG\u2019s review of the company's evidence submission, and the NICE Appraisal Committee\u2019s (AC\u2019s) final decision. The company presented clinical evidence from the PEGASUS trial that assessed the efficacy of pegcetacoplan versus eculizumab. At Week 16, patients in the pegcetacoplan arm had statistically significantly greater change from baseline in haemoglobin levels and a higher rate of transfusion avoidance than patients in the eculizumab arm. Using the PEGASUS trial and Study 302 data (a non-inferiority trial that assessed ravulizumab versus eculizumab), the company conducted an anchored matching-adjusted indirect comparison (MAIC) to indirectly estimate the efficacy of pegcetacoplan versus ravulizumab. The company identified key differences between trial designs and populations that could not be adjusted for using anchored MAIC methods. The company and ERG agreed that the anchored MAIC results were not robust and should not inform decision making. In the absence of robust indirect estimates, the company assumed that ravulizumab had equivalent efficacy to eculizumab in the PEGASUS trial population. Results from the company base-case cost-effectiveness analysis showed that treatment with pegcetacoplan dominated eculizumab and ravulizumab. The ERG considered that the long-term effectiveness of pegcetacoplan was uncertain and ran a scenario assuming that after 1 year the efficacy of pegcetacoplan would be the same as eculizumab; treatment with pegcetacoplan continued to dominate eculizumab and ravulizumab. The AC noted that treatment with pegcetacoplan had lower total costs than treatment with eculizumab or ravulizumab because it is self-administered and reduces the need for blood transfusions. If the assumption that ravulizumab has equivalent efficacy to eculizumab does not hold, then this will affect the estimate of the cost effectiveness of pegcetacoplan versus ravulizumab; however, the AC was satisfied that the assumption was reasonable. The AC recommended pegcetacoplan as an option for the treatment of PNH in adults who have uncontrolled anaemia despite treatment with a stable dose of a C5 inhibitor for \u2265 3 months. Pegcetacoplan was the first technology recommended by NICE via the low ICER FTA process.<\/jats:p>","DOI":"10.1007\/s41669-023-00408-z","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T11:03:04Z","timestamp":1684321384000},"page":"525-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal"],"prefix":"10.1007","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-1535","authenticated-orcid":false,"given":"Rebecca","family":"Bresnahan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4315-7732","authenticated-orcid":false,"given":"Rachel","family":"Houten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4812-1904","authenticated-orcid":false,"given":"Janette","family":"Greenhalgh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9988-2709","authenticated-orcid":false,"given":"Sarah","family":"Nevitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-1003","authenticated-orcid":false,"given":"James","family":"Mahon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0164-103X","authenticated-orcid":false,"given":"Sophie","family":"Beale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5435-8644","authenticated-orcid":false,"given":"Angela","family":"Boland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1694-8106","authenticated-orcid":false,"given":"Devarshi","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9847-1622","authenticated-orcid":false,"given":"Yenal","family":"Dundar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne","family":"McEntee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreyans","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-9779","authenticated-orcid":false,"given":"Nigel","family":"Fleeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7097-8704","authenticated-orcid":false,"given":"Marty","family":"Chaplin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,17]]},"reference":[{"key":"408_CR1","unstructured":"National Institute for Health and Care Excellence. Technology appraisal processes. https:\/\/www.nice.org.uk\/about\/what-we-do\/our-programmes\/nice-guidance\/nice-technology-appraisal-guidance\/process. Accessed 24 June 2022."},{"key":"408_CR2","unstructured":"National Institute for Health and Care Excellence. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. https:\/\/www.nice.org.uk\/guidance\/indevelopment\/gid-ta10651\/documents. Accessed 7 June 2022."},{"issue":"3","key":"408_CR3","doi-asserted-by":"publisher","first-page":"17028","DOI":"10.1038\/nrdp.2017.28","volume":"18","author":"A Hill","year":"2017","unstructured":"Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;18(3):17028.","journal-title":"Nat Rev Dis Primers"},{"issue":"22","key":"408_CR4","doi-asserted-by":"publisher","first-page":"2459","DOI":"10.1182\/blood-2015-06-640995","volume":"126","author":"RA Brodsky","year":"2015","unstructured":"Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126(22):2459\u201365.","journal-title":"Blood"},{"key":"408_CR5","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.2147\/TCRM.S96720","volume":"12","author":"F Al-Ani","year":"2016","unstructured":"Al-Ani F, Chin-Yee I, Lazo-Langner A. Eculizumab in the management of paroxysmal nocturnal hemoglobinuria: patient selection and special considerations. Ther Clin Risk Manag. 2016;12:1161\u201370.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"408_CR6","first-page":"1","volume":"5","author":"F Sahin","year":"2015","unstructured":"Sahin F, Ozkan MC, Mete NG, Yilmaz M, Oruc N, Gurgun A, et al. Multidisciplinary clinical management of paroxysmal nocturnal hemoglobinuria. Am J Blood Res. 2015;5(1):1\u20139.","journal-title":"Am J Blood Res."},{"key":"408_CR7","unstructured":"Orphanet. Paroxysmal nocturnal haemoglobinuria. https:\/\/www.orpha.net\/consor\/cgi-bin\/OC_Exp.php?Lng=GB&Expert=447. Accessed 9 June 2022."},{"key":"408_CR8","doi-asserted-by":"crossref","unstructured":"Jalbert JJ, Chaudhari U, Zhang H, Weyne J, Shammo JM. Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US. Blood. 2019;134(Supplement_1):3407.","DOI":"10.1182\/blood-2019-125867"},{"issue":"19","key":"408_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253\u20138.","journal-title":"N Engl J Med"},{"key":"408_CR10","doi-asserted-by":"crossref","unstructured":"Debureaux P-E, Cacace F, Silva BGP, Barone F, Calado RT, de Fontbrune FS, et al. Hematological response to eculizumab in paroxysmal nocturnal hemoglobinuria: Application of a novel classification to identify unmet clinical needs and future clinical goals. Blood. 2019;134(Supplement_1):3517.","DOI":"10.1182\/blood-2019-125917"},{"key":"408_CR11","unstructured":"Apellis Pharmaceuticals. Annex I Summary of product characteristics (ASPAVELI 1080 mg). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aspaveli-epar-product-information_en.pdf. Accessed 28 June 2022."},{"issue":"11","key":"408_CR12","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1002\/ajh.25960","volume":"95","author":"C de Castro","year":"2020","unstructured":"de Castro C, Grossi F, Weitz IC, Maciejewski J, Sharma V, Roman E, et al. C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab. Am J Hematol. 2020;95(11):1334\u201343.","journal-title":"Am J Hematol"},{"key":"408_CR13","unstructured":"National Institute of Health and Care Excellence. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]: final scope. http:\/\/www.nice.org.uk\/guidance\/gid-ta10651\/documents\/final-scope. Accessed 7 June 2022."},{"issue":"11","key":"408_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, Roth A, Hochsmann B, Panse J, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028\u201337.","journal-title":"N Engl J Med"},{"issue":"8","key":"408_CR15","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1182\/blood-2008-01-133918","volume":"112","author":"RP de Latour","year":"2008","unstructured":"de Latour RP, Mary JY, Salanoubat C, Terriou L, Etienne G, Mohty M, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099\u2013106.","journal-title":"Blood"},{"issue":"6","key":"408_CR16","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S0885-3924(02)00529-8","volume":"24","author":"D Cella","year":"2002","unstructured":"Cella D, Eton DT, Lai J-S, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) Anemia and Fatigue scales. J Pain Symptom Manage. 2002;24(6):547\u201361.","journal-title":"J Pain Symptom Manage"},{"key":"408_CR17","unstructured":"ClinicalTrials.gov. NCT03500549. Study to evaluate the efficacy and safety of APL-2 in patients with paroxysmal nocturnal hemoglobinuria (PNH). www.clinicaltrials.gov\/ct2\/show\/NCT03500549. Accessed 10 June 2022"},{"key":"408_CR18","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Committee papers. Company submission. www.nice.org.uk\/guidance\/ta778\/documents\/committee-papers. Accessed 8 June 2022"},{"key":"408_CR19","unstructured":"National Institute for Health and Care Excellence. Single Technology Appraisal. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]. Committee papers. Clarification questions and company responses. www.nice.org.uk\/guidance\/ta778\/documents\/committee-papers. Accessed 12 June 2022"},{"issue":"1","key":"408_CR20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/ki.2008.414","volume":"75","author":"DE Leaf","year":"2009","unstructured":"Leaf DE, Goldfarb DS. Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int. 2009;75(1):15\u201324.","journal-title":"Kidney Int"},{"issue":"6","key":"408_CR21","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1182\/blood-2018-09-876805","volume":"133","author":"AG Kulasekararaj","year":"2019","unstructured":"Kulasekararaj AG, Hill A, Rottinghaus ST, Langemeijer S, Wells R, Gonzalez-Fernandez FA, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: The 302 study. Blood. 2019;133(6):540\u20139.","journal-title":"Blood"},{"key":"408_CR22","unstructured":"National Institute for Health and Care Excellence Decision Support Unit. NICE DSU Technical Support Document 18: Methods for population-adjusted indirect comparisons in submissions to NICE. www.nicedsu.org.uk\/wp-content\/uploads\/2017\/05\/Population-adjustment-TSD-FINAL.pdf. Accessed 15 June 2022"},{"key":"408_CR23","unstructured":"National Institute for Health and Care Excellence. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria: 1 Recommendations. www.nice.org.uk\/guidance\/ta698\/chapter\/1-Recommendations. Accessed 17 June 2022"},{"key":"408_CR24","unstructured":"National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013: process and methods [PMG9] www.nice.org.uk\/process\/pmg9\/resources\/guide-to-the-methods-of-technology-appraisal-2013-pdf-2007975843781. Accessed 22 June 2022"},{"issue":"9","key":"408_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta18090","volume":"18","author":"L Longworth","year":"2014","unstructured":"Longworth L, Yang Y, Young T, Mulhern B, Hernandez Alava M, Mukuria C, et al. Use of generic and condition-specific measures of health-related quality of life in NICE decision-making: a systematic review, statistical modelling and survey. Health Technol Assess. 2014;18(9):1\u2013224.","journal-title":"Health Technol Assess"},{"issue":"4","key":"408_CR26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jval.2010.10.029","volume":"14","author":"R Ara","year":"2011","unstructured":"Ara R, Brazier JE. Using health state utility values from the general population to approximate baselines in decision analytic models when condition-specific data are not available. Value Health. 2011;14(4):539\u201345.","journal-title":"Value Health."},{"key":"408_CR27","unstructured":"National Institute of Health and Care Excellence. Ravulizumab for treating paroxysmal nocturnal haemoglobinuria [TA698]: Committee papers. www.nice.org.uk\/guidance\/ta698\/documents\/committee-papers. Accessed 14 June 2022."},{"key":"408_CR28","unstructured":"Apellis Pharmaceuticals. Data on file. Pegcetacoplan. Protocol number APL2-302: a phase 3, randomized, multicenter, open-label, active-comparator controlled study to evaluate the efficacy and safety of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria (PNH) Week 16 analysis. May 2020."},{"issue":"4","key":"408_CR29","first-page":"411","volume":"10","author":"E Poggiali","year":"2012","unstructured":"Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfus. 2012;10(4):411\u201322.","journal-title":"Blood Transfus"},{"key":"408_CR30","unstructured":"National Institute for Health and Care Excellence. Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria. Technology appraisal guidance. https:\/\/www.nice.org.uk\/guidance\/ta778\/resources\/pegcetacoplan-for-treating-paroxysmal-nocturnal-haemoglobinuria-pdf-82611503088325. Accessed 17 June 2022."}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-023-00408-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-023-00408-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T09:12:07Z","timestamp":1688980327000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-023-00408-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,17]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["408"],"URL":"https:\/\/doi.org\/10.1007\/s41669-023-00408-z","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"type":"print","value":"2509-4262"},{"type":"electronic","value":"2509-4254"}],"subject":[],"published":{"date-parts":[[2023,5,17]]},"assertion":[{"value":"8 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This project was funded by the National Institute for Health Research Evidence Synthesis Programme as project number NIHR133733. See the Evidence Synthesis Programme website for further project information. . The views and opinions expressed herein are those of the authors and do not necessarily reflect those of the National Institute for Health and Care Excellence or the Department of Health.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors have no competing interests. This article was not externally peer reviewed by <i>PharmacoEconomics\u2014Open<\/i>.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication (from patients\/participants)"}},{"value":"Additional data and material relevant to this appraisal are available on the NICE webpage: . Data are subject to third party restrictions. In the data sharing statement for Hillmen et al. 2021 [] (the primary study publication for the PEGASUS trial), the company state that \u201caccess to patient-level data with qualified external researchers may be available upon request and review once the trial is complete and data are published\u201d.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Rebecca Bresnahan: Project lead and critical appraisal of the clinical evidence. Rachel Houten: Critical appraisal of the economic evidence. Janette Greenhalgh: Critical appraisal of the clinical evidence. Sarah Nevitt: Critical appraisal of the statistical evidence. James Mahon: Critical appraisal of the economic evidence. Sophie Beale: Critical appraisal of the clinical and economic evidence and editorial input. Angela Boland: Critical appraisal of the clinical and economic evidence and editorial input. Devarshi Bhattacharyya: Critical appraisal of the economic evidence. Yenal Dundar: Critical appraisal of the clinical evidence, including search strategies. Joanne McEntee: Critical appraisal of the company submission. Gandhi Shreyans: Critical appraisal of the company submission. Nigel Fleeman: Editorial input. Marty Chaplin: Editorial input. All authors read and commented on draft versions of this paper.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contributions of authors"}}]}}